Articles From: Lilly's Basal Insulin Peglispro Demonstrated HbA1c Superiority against Lantus® in Phase III Trials in Patients with Type 1 Diabetes to MetLife Statement on Preliminary SIFI Designation


Core Phase III clinical trial program complete; BIL showed consistent HbA1c superiority against comparators Lilly expects U.S. and European regulatory submissions by end of Q1 2015 INDIANAPOLIS , Sept.
Sign-up for Lilly's Basal Insulin Peglispro Demonstrated HbA1c Superiority against Lantus® in Phase III Trials in Patients with Type 1 Diabetes investment picks
HOUSTON, Sept.
Sign-up for LINN Energy Announces $1.0 Billion Senior Notes Offering investment picks
HOUSTON, Sept.
Sign-up for LINN Energy Announces Pricing of $1.1 Billion of Senior Notes investment picks
LAS VEGAS, Sept.
Sign-up for LiveDeal Inc. to Retain Byron Hsu as CEO and CTO of Subsidiary ModernEveryday investment picks
http://at.marketwire.com/accesstracking/AccessTrackingLogServlet?docid=0966414001&sourceType=1 http://www.ccnmatthews.com/logos/20080429-LUNLOGO.JPG TORONTO, ONTARIO --
Sign-up for Lundin Reports 2014 Mineral Reserve & Resource Estimate Update investment picks
HOUSTON and LONDON , Sept.
Sign-up for LyondellBasell to Address UBS Best of Americas 2014 Conference investment picks
2014/9/4
Data Integration across the Supply Chain: From Art, to Part, to Fulfillment LATROBE, Pa.
Sign-up for Made In The Cloud: Meet The Companies Leading The Manufacturing Sector's Digital Revolution investment picks
2014/9/4
YAHUD, Israel , Sept.
Sign-up for Magal Security Systems Reports Second Quarter 2014 Financial Results investment picks
Agreement Signed with Indiana Farm for the Sterilization of Manure and Use of MagneGas® TAMPA, Fla.
Sign-up for MagneGas Signs Agreement with Major Hog Farm for Demo and Sale of Sterilization System investment picks
Generates $11.0 Million Realized Gain and 25.1% Internal Rate of Return from Exit of Investment in American Sensor Technologies, Inc. HOUSTON , Sept.
Sign-up for Main Street Announces Exit of Portfolio Investment investment picks
Mallinckrodt (NYSE: MNK) today reported that a Phase 3 efficacy trial of investigational MNK-155 met the study’s primary endpoint of improved pain scores vs.
Sign-up for Mallinckrodt Pharmaceutical’s MNK-155, an Extended-Release Hydrocodone/Acetaminophen Combination, Shows Efficacy in Phase 3 Acute Pain Trial investment picks
Group Presentation Set for 11:30 AM PT BRIDGEVIEW, Ill.
Sign-up for Manitex International, Inc. to Present at the RBC Global Industrials Conference on September 10, 2014 investment picks
NEW YORK, Sept.
Sign-up for MarketAxess Announces Monthly Volume Statistics for August 2014 investment picks
AKRON, Ohio , Sept.
Sign-up for Maryland Educators Reminded to Apply for Education Grants by September 19 investment picks
Mattress Firm Holding Corp.
Sign-up for Mattress Firm Announces Second Fiscal Quarter Financial Results investment picks
2014/9/4
NEW YORK , Sept.
Sign-up for MDC Partners to Present at the Goldman Sachs 23rd Annual Communacopia Conference investment picks
Mead Johnson Nutrition Company (NYSE: MJN) announced today that its board of directors has declared a regular quarterly common stock dividend of $0.375 per share for the quarter ending September 30, 2014.
Sign-up for Mead Johnson Board of Directors Declares Dividend investment picks
2014/9/4
MEDIA ADVISORY - TD Bank Group Executive to Present at the CIBC 13th Annual Eastern Institutional Investor Conference Canada NewsWire TORONTO , Sept.
Sign-up for MEDIA ADVISORY - TD Bank Group Executive to Present at the CIBC 13th Annual Eastern Institutional Investor Conference investment picks
Health Coaches 'Walk Across America' to Spread the Importance of a Healthy Lifestyle OWINGS MILLS, Md.
Sign-up for Medifast's Take Shape For Life Division Hosts 2nd Annual National "Discover Your Optimal Health" Day investment picks
Merck (NYSE:MRK), known as MSD outside the United States and Canada, today announced that the U.S. Food and Drug Administration (FDA) has approved KEYTRUDA® (pembrolizumab) at a dose of 2 mg/kg every three weeks for the treatment of patients with unresectable or metastatic melanoma and disease progression following ipilimumab and, if BRAF V600 mutation positive, a BRAF inhibitor.
Sign-up for Merck Receives Accelerated Approval of KEYTRUDA® (pembrolizumab), the First FDA-Approved Anti-PD-1 Therapy investment picks
Merck (NYSE:MRK), known as MSD outside the United States and Canada, announced today that the U.S. Food and Drug Administration (FDA) has designated relebactam (previously known as MK-7655), the company’s investigational beta-lactamase inhibitor, as a Qualified Infectious Disease Product (QIDP) with designated Fast Track status.
Sign-up for Merck’s Investigational Beta-lactamase Inhibitor Relebactam (MK-7655) Granted Qualified Infectious Disease Product (QIDP) and Fast Track Designations by FDA investment picks
BOSTON, Sept.
Sign-up for Merger With Hillshire Moves Tyson Forward Faster investment picks
http://media.marketwire.com/attachments/201211/54409_Methodelogo.jpg http://at.marketwire.com/accesstracking/AccessTrackingLogServlet?PrId=1142033&ProfileId=051205&sourceType=1 CHICAGO, IL --
Sign-up for Methode Electronics, Inc. Reports Fiscal 2015 First-Quarter Sales Growth of 30 Percent and Income From Operations Growth of 87 Percent investment picks
MetLife, Inc. (NYSE:MET) Chairman, President and Chief Executive Officer Steven A.
Sign-up for MetLife Statement on Preliminary SIFI Designation investment picks
Premium Membership: Features and Benefits
Wide-Moat Screener for Stocks

Put a moat around your portfolio. Sniff out the most promising opportunities that can ride through any market.

Gold Medalist Screener for Funds

Narrow the available universe of 5000 funds to the top rated gold and silver. Then, sort for manager tenure, expense ratio, risk and return to create your own index-beating fund watchlist.

Thousands of Premium Analyst Reports

While many of our competitors measure a stock's worth with a computer program, Morningstar's staff of 150+ analyst sift through company fillings, financial data and a wealth of other sources to deliver an unvarnished review of any investment. In fact, twelve Morningstar analysts have been recognized by WSJ as "Best on the Street" in the US.

Premium Portfolio Monitor

Make decisions with confidence. Load your investments into our research center and automatically connect to all our proprietary tools and data points.

Mobile

Never be without critical research. Free with your active membership, take our Premium data and guidance wherever you go with Morningstar for iPad®, iPhone®, and Android apps.

Morningstar's Guarantee

We're looking out for you. If after your 14-day free trial, you find that a Morningstar Premium membership is not for you, cancel any time and we'll be happy to refund the unused portion - no questions asked.

Go Premium!
Exclusive Premium Member Benefits
Get the best thinking of 150+ disciplined
objective, experienced analysts-dedicated to
specific industries and securities.
+2,500 Analyst Reports
Wide Moat Screener for Stocks
Medalist Screener for Funds
Premium Portfolio Manager with X-Ray & Monitor
Premium eNewsletters
Morningstar Basic Benefits (All)
Sign up now - No charge for the first 14 days
Articles From: Lilly's Basal Insulin Peglispro Demonstrated HbA1c Superiority against Lantus® in Phase III Trials in Patients with Type 1 Diabetes to MetLife Statement on Preliminary SIFI Designation
Name |  Ticker |  Star Rating |  Market Cap |  Stock Type |  Sector |  Industry Star Rating |  Investment Style |  Total Assets |  Category |  Top Holdings |  Top Sectors |  Symbol |  Title Star Rating |  Category |  Total Assets |  Top Holdings |  Top Sectors |  Symbol |  Name Topic |  Sector |  Key Indicators |  User Interest |  Market Cap |  Industry Name |  Ticker |  Star Rating |  Market Cap |  Stock Type |  Sector |  Industry Star Rating |  Investment Style |  Total Assets |  Category |  Top Holdings |  Top Sectors |  Symbol / Ticker |  Title Star Rating |  Category |  Total Assets |  Symbol / Ticker |  Name Title |  Date |  Author |  Collection |  Popularity |  Interest Title |  Date |  Company |  Symbol |  Interest |  Popularity Title |  Date |  Company |  Symbol |  Interest |  Popularity Topic |  Sector |  Key Indicators |  User Interest |  Market Cap |  Industry Name |  Ticker |  Popularity |  Our Choices